Bioengineered in vitro skeletal muscles as new tools for muscular dystrophies preclinical studies

J Tissue Eng. 2021 Feb 10:12:2041731420981339. doi: 10.1177/2041731420981339. eCollection 2021 Jan-Dec.

Abstract

Muscular dystrophies are a group of highly disabling disorders that share degenerative muscle weakness and wasting as common symptoms. To date, there is not an effective cure for these diseases. In the last years, bioengineered tissues have emerged as powerful tools for preclinical studies. In this review, we summarize the recent technological advances in skeletal muscle tissue engineering. We identify several ground-breaking techniques to fabricate in vitro bioartificial muscles. Accumulating evidence shows that scaffold-based tissue engineering provides topographical cues that enhance the viability and maturation of skeletal muscle. Functional bioartificial muscles have been developed using human myoblasts. These tissues accurately responded to electrical and biological stimulation. Moreover, advanced drug screening tools can be fabricated integrating these tissues in electrical stimulation platforms. However, more work introducing patient-derived cells and integrating these tissues in microdevices is needed to promote the clinical translation of bioengineered skeletal muscle as preclinical tools for muscular dystrophies.

Keywords: Skeletal muscle; biomaterials; drug screening platforms; muscular dystrophy; tissue engineering.

Publication types

  • Review